SCHEMBL2002341

SCHEMBL2002341

O=C1NCCC=C1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23610158 0.86
SCHEMBL6636855 0.70
SCHEMBL21001898 0.70
SCHEMBL23610173 0.70
SCHEMBL8384534 0.70
SCHEMBL6471258 0.67
SCHEMBL15108946 0.65
SCHEMBL23048402 0.65 PARP10 (0.36)
SCHEMBL20506562 0.65
SCHEMBL7906048 0.65 EEF2K (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240100031-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VIRAL INFECTIONS CONTAINING PIPERLONGUMINE-BASED COMPOUND AS ACTIVE INGREDIENT HUSCION CO., LTD. (KR) 2024-03-28 US disclosed
CN-117466804-A New process for synthesizing apixaban intermediate 江苏阿尔法药业股份有限公司 2024-01-30 CN disclosed
US-11878971-B2 Piperlongumine-based compound and immuno regulator comprising the same HUSCION CO., LTD. (KR) 2024-01-23 US disclosed
WO-2023055020-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VASCULAR DISEASES, COMPRISING PIPERLONGUMINE-BASED COMPOUND AS ACTIVE INGREDIENT 주성수 2023-04-06 WO disclosed
US-11485725-B2 Derivatives of piperlongumine and uses thereof AURANSA INC. (US) 2022-11-01 US disclosed
WO-2022145707-A1 PIPERLONGUMINE-BASED COMPOUND AND IMMUNOMODULATOR COMPRSING SAME 주식회사 휴사이온 2022-07-07 WO disclosed
US-20220213080-A1 PIPERLONGUMINE-BASED COMPOUND AND IMMUNO REGULATOR COMPRISING THE SAME HUSCION CO., LTD. (KR) 2022-07-07 US disclosed
US-20220213080-A1 PIPERLONGUMINE-BASED COMPOUND AND IMMUNO REGULATOR COMPRISING THE SAME HUSCION CO., LTD. (KR) 2022-07-07 US disclosed
WO-2022145923-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VIRAL INFECTIONS CONTAINING PIPERLONGUMINE-BASED COMPOUND AS ACTIVE INGREDIENT 주식회사 휴사이온 2022-07-07 WO disclosed
EP-4023301-A2 PIPERLONGUMINE-BASED COMPOUND AND IMMUNO REGULATOR COMPRISING THE SAME Huscion Co., Ltd. (KR) 2022-07-06 EP disclosed
US-20050124602-A1 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-06-09 US disclosed
US-20040254158-A1 Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders BRISTOL-MYERS SQUIBB COMPANY 2004-12-16 US disclosed
US-20040220174-A1 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-11-04 US disclosed
EP-1467984-A2 SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO (3,4-C) PYRID-2-ONES Bristol-Myers Squibb Company (US) 2004-10-20 EP disclosed
WO-2004083177-A2 LINEAR CHAIN SUBSTITUTED MONOCYCLIC AND BICYCLIC DERIVATIVES AS FACTOR XA INHIBITORS BRYSTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 WO disclosed
WO-2003099276-A1 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 WO disclosed
US-20030191115-A1 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-10-09 US disclosed
US-20030181466-A1 Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones BRISTOL-MYERS SQUIBB COMPANY 2003-09-25 US disclosed
WO-2003049681-A2 SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO [3,4-C] PYRID-2-ONES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-19 WO disclosed
WO-2003049681-A2 SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO [3,4-C] PYRID-2-ONES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-19 WO disclosed